OCA
KROS icon

Octagon Capital Advisors’s Keros Therapeutics KROS Stock Holding History

Octagon Capital Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-152,249
Closed -$4.21M – 38
2022
Q2 		$4.21M Sell
152,249
-187,965
-55% -$8.25M 1.12% 14
2022
Q1 		$18.5M Hold
340,214
– – 4% 8
2021
Q4 		$19.9M Buy
+340,214
New +$17M 3.87% 8

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Octagon Capital Advisors's KROS Position: Q3 2022 in Review

Octagon Capital Advisors sold out of Keros Therapeutics (KROS) in Q3 2022, closing a stake of 152,249 shares — an estimated $4.21M sold.

Octagon Capital Advisors first reported a position in KROS in Q4 2021 and held it in 3 quarters. The position peaked at $19.9M in Q4 2021. 113 funds tracked by Wall St. Rank hold KROS as of Q3 2022.

  • Octagon Capital Advisors reported no remaining Keros Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Octagon Capital Advisors sold 152,249 Keros Therapeutics shares in Q3 2022, an estimated $4.21M.
  • Octagon Capital Advisors first reported a position in Keros Therapeutics in Q4 2021 and held it in 3 quarters.
  • Octagon Capital Advisors's Keros Therapeutics position peaked at $19.9M in Q4 2021.
  • 113 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2022.

Based on Octagon Capital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.